Cathie Wood's Ark Adds Over $19M Worth Of Moderna Shares After Thursday's 21% Plunge On Guidance Cut
Cathie Wood's Ark Adds Over $19M Worth Of Moderna Shares After Thursday's 21% Plunge On Guidance Cut
COVID-19 vaccine maker Moderna, Inc. (NASDAQ:MRNA) fell over 21% on Thursday after the company reduced its revenue guidance for the year, citing a highly competitive respiratory vaccine market in the U.S. and weak COVID-19 vaccine sales in Europe.
COVID-19疫苗製造商Moderna，Inc.（NASDAQ：MRNA）由於公司調低全年營業收入指導，稱美國競爭激烈的呼吸道疫苗市場和歐洲COVID-19疫苗銷售疲軟，週四股價下跌超過21%。
What Happened: Moderna stock plunged 21.01% to $94.17 on Thursday and fell an incremental 1.73% to $92.54 in premarket trading on Friday, according to Benzinga Pro data.
現代a股在週四下跌了21.01%，至94.17美元，並在週五盤前交易中額外下跌1.73%，至92.54美元，根據Benzinga Pro的數據。
Cathie Wood's Ark Invest capitalized on the weakness and piled into the stock. On Thursday two of Ark's actively managed exchange-traded funds – the Ark Innovation ETF (NYSE:ARKK) and the ARK Genomic Revolution ETF (CBOE: ARKG), bought 202,991 shares of Moderna, valued at $19.12 million.
Cathie Wood的Ark Invest利用這一弱勢，押注了這個股票。週四，Ark的兩隻主動交易型基金 - Ark Innovation ETF（紐交所：ARKK）和ARk Genomic Revolution ETF（CBOE：ARKG）購買了Moderna的202,991股，價值1912萬美元。
The buying is in line with Ark's strategy of using any potential weakness as a buying opportunity in its core portfolio holdings.
該購買符合Ark使用其核心投資組合中任何潛在弱勢作爲購買機會的策略。
Moderna is ARKK's 24th biggest holding in value terms, with the flagship fund holding 736,884 shares valued at $69.39 million. ARKG holds 399,287 Modena shares valued at $37.60 million.
現代a股是ARKK價值排名第24大的持股，旗艦基金持有736,884股，價值6939萬美元。 ARKG持有399,287股Modena的股份，價值3760萬美元。
Why It's Important: Moderna, which is one of the pioneers of the mRNA new-vaccine technology, was among the frontrunners that launched vaccines for the virus causing the COVID-19 pandemic. The early-mover advantage has helped the company to make outsized profits from selling the vaccine.
爲什麼這很重要：Moderna是核糖核酸（mRNA）新疫苗技術的先驅之一，是針對導致COVID-19大流行的病毒推出疫苗的領跑者之一。先發優勢幫助該公司從出售疫苗中獲得了超額利潤。
As the pandemic abated, the company has done well to diversify its revenue stream. In late May, it received FDA approval for its respiratory syncytial vaccine. The company is also developing a slew of personalized cancer vaccines in collaboration with Merck & Co. (NYSE:MRK).
隨着大流行的消退，該公司在多元化營收渠道方面表現出色。5月下旬，它獲得了呼吸道合胞病毒疫苗的FDA批准。該公司還與Merck＆Co.（紐約證券交易所：MRK）合作開發一批個性化癌症疫苗。
- Cathie Wood's Ark Invest Sells $14.7M Worth Of Coinbase Shares And $8.5M Worth Of Palantir Stock — Also Sells Robinhood Shares But Loads Up On AMD
- 凱瑟琳·伍德的Ark投資公司出售了價值1470萬美元的Coinbase股份和價值850萬美元的palantir股票-還出售了Robinhood股份，但增持了AMD股份
Photo via Wikimedia Commons
照片通過Wikimedia Commons